Changchun High-tech: Subsidiary GenSci161's application for domestic production of injection solution drugs registered for clinical trials has been approved.

Changchun Hi-tech announced that its subsidiary, Jin Sai Pharmaceutical's GenSci161 injection, a domestically produced drug, has received approval for clinical trial registration. GenSci161 injection is a Class 1 biologic product developed independently by Jin Sai Pharmaceutical, intended for the treatment of endometriosis and moderate to severe hidradenitis suppurativa.